Vaccine news from FiercePharma
News
GSK gets bad press in U.S., Argentina
Families in Argentina are saying GlaxoSmithKline tricked them into participating in an experimental vaccine trial by telling them their children were receiving medical treatment, according to an ABC... Read more...
Novartis buys Protez, invests in vaccines
Novartis AG is purchasing U.S.-based antibiotics developer Protez Pharmaceuticals Inc. (Pennsylvania) for a base price of $100 million, but has promised up to $300 million in additional payments
... Read more...GSK nabs EU approval for pandemic shot
Put GlaxoSmithKline at the head of the list of vaccine-makers able to profit from a potential flu pandemic. The company just got EU go-ahead to market its H5N1 vaccine, Prepandrix, becoming the first... Read more...
Novartis injects $816.5M in vaccine plant
Novartis is pledging to sink €600 million ($816.5 million) into new and expanded facilities in Italy, a local newspaper reports. The company would upgrade its vaccine research center in Siena to... Read more...
Get more Vaccine coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
